decemb
novel
coronaviru
diseas
outbreak
caus
renam
sever
acut
respiratori
syndrom
coronaviru
start
china
pandem
world
newli
appear
infecti
diseas
earli
effort
focus
viru
identif
describ
epidemiolog
characterist
clinic
cours
prognost
critic
ill
case
treat
sick
among
case
report
mainland
china
case
updat
februari
mild
sever
critic
estim
overal
case
fatal
rate
cfr
death
report
among
mild
sever
case
cfr
among
critic
case
studi
follow
strengthen
report
observ
studi
epidemiolog
strobe
guidelin
total
patient
recruit
studi
two
section
one
sever
patient
anoth
mild
moder
patient
chongq
public
health
medic
center
cphmc
design
hospit
treatment
chongq
central
area
patient
transfer
two
section
januari
februari
enrol
cohort
studi
final
followup
februari
laboratoryconfirm
infect
accord
interim
guidanc
clinic
specimen
includ
nasopharyng
swab
sputum
blood
urin
stool
collect
period
day
interv
admiss
specimen
nine
patient
among
patient
visit
admit
southwest
hospit
jan
jan
also
collect
transfer
cphmc
flow
diagram
studi
design
present
epidemiolog
data
obtain
standard
investig
form
includ
patient
demograph
symptom
histori
relev
exposur
clinic
radiolog
characterist
laboratori
find
daili
inform
regard
symptom
clinic
cours
medic
patient
vital
sign
complic
treatment
outcom
data
obtain
standard
case
report
form
medic
record
patient
data
check
physician
two
clinic
assist
studi
approv
ethic
committe
cphmc
document
conduct
accord
declar
helsinki
principl
written
inform
consent
obtain
subject
viral
rna
extract
patient
specimen
viral
rna
mini
kit
qiagen
hilden
germani
specimen
handl
biosafeti
cabinet
accord
laboratori
biosafeti
guidelin
quantit
realtim
reversetranscriptas
polymeras
chain
reaction
qrtpcr
gene
perform
qrtpcr
kit
bgishenzhen
china
specimen
consid
posit
cycl
threshold
c
valu
neg
result
undetermin
c
valu
qrtpcr
convert
rna
copi
number
standard
curv
base
c
valu
refer
plasmid
dna
serum
specif
igm
igg
antibodi
analyz
elisa
kit
livzon
diagnost
inc
zhuhai
china
use
nucleocapsid
protein
np
antigen
follow
instruct
manual
od
valu
measur
titer
calcul
three
neg
two
posit
control
includ
plate
transmiss
electron
microscopi
tem
perform
directli
nasopharyng
swab
sputum
stool
patient
negativestain
tem
specimen
supernat
fix
paraformaldehyd
stain
phosphotungst
acid
formvarcarbonco
grid
thinsect
tem
specimen
pellet
fix
paraformaldehyd
fix
osmium
tetroxid
embed
epon
resin
ultrathinsect
stain
uranyl
acet
lead
citrat
separ
negativestain
grid
ultrathin
section
observ
use
plu
jeol
japan
hitachi
japan
tem
respect
defin
ill
onset
first
day
report
symptom
consist
incub
period
defin
time
exposur
onset
ill
construct
epidem
curv
date
exposur
ill
onset
key
date
relat
epidem
identif
diseas
process
r
softwar
key
timetoev
differ
sever
nonsever
patient
estim
fit
lognorm
gamma
weibul
normal
distribut
onesampl
kolmogorovsmirnov
test
continu
variabl
use
onesampl
pairedsampl
ttest
categor
variabl
use
mannwhitney
u
test
chisquar
test
fisher
exact
test
also
perform
univari
multivari
logist
regress
analysi
explor
risk
factor
associ
diseas
sever
statist
signific
set
p
statist
analys
done
use
spss
softwar
graphpad
prism
total
patient
clinic
specimen
enrol
longitudin
studi
see
supplementari
figur
strategi
demograph
epidemiolog
characterist
list
tabl
median
age
year
rang
half
patient
men
twentyf
patient
underli
diseas
common
symptom
ill
onset
fever
cough
epidem
curv
onset
ill
among
cohort
patient
indic
signific
decreas
number
import
local
case
chongq
metropolitan
area
wuhan
citi
shutdown
sinc
jan
supplementari
figur
twentysix
patient
infect
household
contact
famili
cluster
tabl
estim
median
incub
period
day
rang
day
gender
age
differ
incub
period
howev
children
prolong
incub
period
supplementari
figur
key
timetoev
distribut
list
supplementari
figur
clinic
characterist
patient
admiss
shown
supplementari
tabl
hospit
nonsever
normal
temperatur
laboratori
find
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
admiss
list
supplementari
tabl
patient
sever
diseas
promin
laboratori
abnorm
nonsever
diseas
patient
receiv
antivir
treatment
combin
lopinavirritonavir
use
oxygen
support
given
empir
antibiot
treatment
sever
patient
receiv
oxygen
support
receiv
mechan
ventil
given
antibiot
treatment
given
systemat
corticosteroid
treatment
supplementari
tabl
end
studi
feb
sever
patient
nonsever
patient
discharg
patient
die
total
sampl
patient
collect
includ
nasopharyng
swab
sputum
stool
urin
plasma
sampl
tabl
rna
level
nasopharyng
swab
fig
sputum
fig
stool
fig
peak
first
week
day
day
symptom
onset
respect
rna
level
typic
began
decreas
higher
viral
load
invers
relat
c
valu
detect
sputum
nasopharyng
stool
peak
load
copi
per
mililit
respect
supplementari
figur
viral
load
stratifi
sever
nonsever
patient
also
depict
fig
median
durat
rna
shed
day
rang
nasopharyng
swab
day
rang
sputum
day
rang
stool
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
neg
timepoint
supplementari
figur
addit
six
patient
confirm
rna
posit
sputum
bronchoalveolar
lavag
fluid
balf
stool
supplementari
figur
among
patient
cohort
symptom
progress
shed
ill
onset
depict
number
patient
report
cough
fever
appear
align
proport
detect
rna
nasopharyng
swab
sputum
fig
number
patient
posit
stoolrna
appear
align
report
cough
expector
diarrhea
fig
found
typic
coronavir
particl
sputum
directli
transmiss
electron
microscopi
neg
stain
ultrathin
section
prepar
shown
exclud
subsequ
dynam
antibodi
analysi
patient
could
categor
strong
respond
peak
titer
cutoff
valu
weak
respond
peak
titer
fold
cutoff
valu
nonrespond
peak
titer
cutoff
valu
igm
fig
igg
fig
nonrespond
weak
respond
strong
respond
tabl
proport
strong
respond
significantli
higher
proport
weak
respond
significantli
lower
sever
patient
nonsever
patient
igm
p
igg
p
similarli
titer
serum
igm
igg
continu
significantli
higher
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
sever
patient
nonsever
patient
along
time
igm
p
igg
p
fig
fig
tabl
notabl
proport
viral
clearanc
day
antibodi
appear
significantli
higher
nonsever
patient
sever
patient
igm
vs
p
igg
vs
p
furthermor
weak
respond
igg
antibodi
significantli
higher
viral
clearanc
rate
strong
respond
p
fig
fig
tabl
multivari
model
includ
avail
data
patient
report
fever
tabl
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
cohort
chongq
citi
provid
inform
epidemiolog
clinic
characterist
outsid
wuhan
diseas
outbreak
first
found
featur
chongq
case
differ
earli
case
report
wuhan
china
exampl
case
identifi
admit
hospit
earlier
stage
wuhan
case
case
firstor
secondgener
case
clear
contact
histori
incub
period
chang
spread
wuhan
sex
age
differ
howev
although
none
three
children
develop
sever
type
diseas
increas
sensit
qrtpcr
assay
interestingli
stool
shed
seem
align
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
cough
expector
diarrhea
report
demonstr
viabl
viru
could
isol
stool
data
implic
stool
viral
rna
may
directli
swallow
sputum
infect
intestin
mucosa
bile
duct
visual
typic
coronaviru
sputum
patient
directli
electron
microscopi
demonstr
util
tradit
techniqu
clinic
diagnosi
infect
studi
also
determin
igm
igg
antibodi
nucleocapsid
protein
dynam
patient
acut
earli
convalesc
phase
although
observ
profil
antibodi
nucleocapsid
protein
consist
common
find
regard
acut
viral
infecti
diseas
howev
uniqu
find
may
novel
import
understand
infect
first
observ
three
type
antibodi
respons
patient
strong
weak
nonrespons
second
found
earlier
respons
higher
antibodi
titer
higher
proport
strong
respond
igm
igg
significantli
associ
diseas
sever
third
weak
respond
igg
antibodi
significantli
higher
viral
clearanc
rate
strong
respond
data
indic
strong
antibodi
respons
associ
diseas
sever
weak
antibodi
respons
associ
viral
clearanc
resembl
sar
mer
profil
antibodi
may
help
diagnosi
epidemiolog
survey
howev
role
variou
antibodi
relat
diseas
sever
immunolog
direct
treatment
vaccin
efficaci
deserv
urgent
investig
nevertheless
limit
studi
first
largescal
multicent
cohort
region
need
verifi
preliminari
find
second
viabil
viru
stool
plasma
urin
role
pathogenesi
transmiss
need
clarifi
third
antibodi
spike
envelop
protein
role
protect
infect
reinfect
still
unknown
wait
futur
investig
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
day
count
symptom
onset
ns
nasopharyng
swab
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
indic
cycl
threshold
c
valu
invers
relat
viral
rna
copi
number
correspond
copi
number
detail
see
figur
blue
dash
line
indic
detect
limit
c
valu
symbol
error
bar
denot
mean
standard
error
c
valu
blue
arrow
indic
averag
time
reach
undetect
symptom
onset
viral
load
nasopharyng
swab
sputum
stool
sever
nonsever
patient
also
depict
panel
e
f
respect
symbol
indic
mean
c
valu
panel
g
show
prolong
viral
shed
sputum
patient
cohort
continu
sampl
sputum
nasopharyng
swab
dark
dash
line
togeth
black
arrow
indic
exampl
patient
still
rnaposit
sputum
day
ill
onset
much
higher
nasopharyng
swab
patient
panel
h
show
symptom
report
cough
measur
fever
diarrhea
progress
viral
shed
nasopharyng
swab
sputum
stool
ill
onset
cohort
ultrathinsect
negativestain
grid
observ
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
transmiss
electron
microscopi
hitachi
japan
plu
jeol
corp
japan
respect
